CA2608702C - Ergoline derivatives and their use as chemokine receptor ligands - Google Patents

Ergoline derivatives and their use as chemokine receptor ligands Download PDF

Info

Publication number
CA2608702C
CA2608702C CA2608702A CA2608702A CA2608702C CA 2608702 C CA2608702 C CA 2608702C CA 2608702 A CA2608702 A CA 2608702A CA 2608702 A CA2608702 A CA 2608702A CA 2608702 C CA2608702 C CA 2608702C
Authority
CA
Canada
Prior art keywords
optionally
substituted
formula
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2608702A
Other languages
English (en)
French (fr)
Other versions
CA2608702A1 (en
Inventor
Rolf Baenteli
Fraser Glickman
Jiri Kovarik
Ian Lewis
Markus Streiff
Gebhard Thoma
Hans-Guenter Zerwes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2608702A1 publication Critical patent/CA2608702A1/en
Application granted granted Critical
Publication of CA2608702C publication Critical patent/CA2608702C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
CA2608702A 2005-05-31 2006-05-29 Ergoline derivatives and their use as chemokine receptor ligands Expired - Fee Related CA2608702C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0511060.6A GB0511060D0 (en) 2005-05-31 2005-05-31 Organic compounds
GB0511060.6 2005-05-31
PCT/EP2006/005106 WO2006128658A1 (en) 2005-05-31 2006-05-29 Ergoline derivatives and their use as chemokine receptor ligands

Publications (2)

Publication Number Publication Date
CA2608702A1 CA2608702A1 (en) 2006-12-07
CA2608702C true CA2608702C (en) 2013-10-15

Family

ID=34834898

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2608702A Expired - Fee Related CA2608702C (en) 2005-05-31 2006-05-29 Ergoline derivatives and their use as chemokine receptor ligands

Country Status (12)

Country Link
US (1) US7666877B2 (enExample)
EP (1) EP1893611A1 (enExample)
JP (1) JP5121703B2 (enExample)
KR (1) KR20080013971A (enExample)
CN (1) CN101184754B (enExample)
AU (1) AU2006254395B2 (enExample)
BR (1) BRPI0611489A2 (enExample)
CA (1) CA2608702C (enExample)
GB (1) GB0511060D0 (enExample)
MX (1) MX2007015084A (enExample)
RU (1) RU2416613C2 (enExample)
WO (1) WO2006128658A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
JP5874124B2 (ja) 2010-06-28 2016-03-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 緑内障の処置に使用するための薬学的組成物
CA2838991A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
WO2013095708A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
AU2012382929A1 (en) * 2012-06-22 2015-02-05 Map Pharmaceuticals, Inc. Novel cabergoline derivatives
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
AU2016209490B2 (en) 2015-01-20 2020-09-03 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
EP3630758A1 (en) 2017-06-01 2020-04-08 Xoc Pharmaceuticals, Inc Ergoline derivatives for use in medicine
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2022232093A1 (en) 2021-04-30 2022-11-03 Mind Medicine, Inc. Lsd salt crystal forms
AU2022331317B2 (en) 2021-08-19 2025-09-11 Definium Therapeutics US, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
RU2329263C2 (ru) 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida

Also Published As

Publication number Publication date
RU2007147597A (ru) 2009-07-20
CA2608702A1 (en) 2006-12-07
EP1893611A1 (en) 2008-03-05
MX2007015084A (es) 2008-01-17
BRPI0611489A2 (pt) 2010-11-23
JP5121703B2 (ja) 2013-01-16
RU2416613C2 (ru) 2011-04-20
WO2006128658A1 (en) 2006-12-07
KR20080013971A (ko) 2008-02-13
GB0511060D0 (en) 2005-07-06
JP2008545725A (ja) 2008-12-18
CN101184754B (zh) 2010-12-22
US20090018127A1 (en) 2009-01-15
AU2006254395B2 (en) 2010-09-09
US7666877B2 (en) 2010-02-23
CN101184754A (zh) 2008-05-21
AU2006254395A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
CA2608702C (en) Ergoline derivatives and their use as chemokine receptor ligands
KR100616039B1 (ko) 비피페리디닐-유도체 및 이의 케모킨 수용체 억제제로서의 용도
CA2057504C (en) Process for preparing new n-acyl-2,3-benzodiazepine derivatives, their acid addition salts and pharmaceutical compositions containing the same
Gilman et al. Atropisomers of 1, 4-benzodiazepines. Synthesis and resolution of a diazepam-related 1, 4-benzodiazepine
NZ240993A (en) 3,7-disubstituted indoles and analogues and pharmaceutical compositions
WO2010085597A1 (en) Macrocyclic compounds and their use as kinase inhibitors
Malpass et al. Synthesis and nicotinic acetylcholine-binding properties of epibatidine homologues: homoepibatidine and dihomoepibatidine
AU2002302511A1 (en) Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
JP2025531844A (ja) Ｅｎｌ／ａｆ９ ｙｅａｔｓ及びｆｌｔ３の阻害剤
CA2632670A1 (en) Bridged n-cyclic sulfonamido inhibitors of gamma secretase
PT100658A (pt) Derivados de hidro-isoquinolina e processo para a sua preparacao
US20040067959A1 (en) Morphinoid derivatives as delta-opioid agonists and antagonists
Jonas et al. Synthesis and pharmacological evaluation of enantiomerically pure endo-configured KOR agonists with 2-azabicyclo [3.2. 1] octane scaffold
WO2024081961A2 (en) Ester analogs of psilocin, processes for the preparation thereof, and methods of use
Doisy et al. Synthesis and benzodiazepine receptor (ω receptor) affinities of 3-substituted derivatives of pyrrolo [2, 3-c] pyridine-5-carboxylate, a novel class of ω1 selective ligands
EP0630893B1 (en) N,n'-disubstituted amide derivative
US5679674A (en) Optically active thiomorpholine derivatives
Nelson et al. Synthesis and Opioid Receptor Affinity of a Series of Aralkyl Ethers of 6. alpha.-and 6. beta.-Naltrexol
Mieczkowski et al. A traceless solid-supported synthesis of novel pyrazinediazepinedione derivatives
WO2025045281A2 (zh) 苯并氮杂䓬酮类化合物及其用途
KUROITA et al. Synthesis and structure-activity relationships of 2, 3-dihydrobenzofuran-7-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150529